Clioquinol
chemical compound
Clioquinol (iodochlorhydroxyquin or iodochlorohydroxyquinoline) tradename Entero-Vioform is an antifungal drug and antiprotozoal drug. It is neurotoxic in large doses. It is a member of a family of drugs called hydroxyquinolines which inhibit certain enzymes related to DNA replication. The drugs have been found to have activity against both viral and protozoal infections.
Antiprotozoal use
A 1964 report described the use of clioquinol in both the treatment and prevention of shigella infection and Entamoeba histolytica infection in institutionalized individuals at Sonoma State Hospital in California. The report indicates 4000 individuals were treated over a 4-year period with few side effects.
Several recently reported journal articles describing its use as an antiprotozoal include:
A 2005 reference to its use in treating a Dutch family for Entamoeba histolytica infection.
A 2004 reference to its use in the Netherlands in the treatment of Dientamoeba fragilis infection.
A 1979 reference to the use in Zaire in the treatment of Entamoeba histolytica infection.
Subacute myelo-optic neuropathy
Clioquinol's use as an antiprotozoal drug has been restricted or discontinued in some countries due to an event in Japan where over 10,000 people developed subacute myelo-optic neuropathy (SMON) between 1957 and 1970.
“Clioquinol” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Clioquinol, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Clioquinol” is worth following because a concise public description often conceals a longer documentary argument. Here, Clioquinol, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jul 9, 2026. The linked authority identifier is Q5134338. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1964, 2005, 2004 and 1979.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Clioquinol”, its source revision and the description used here.
- Expand the search: follow Clioquinol primary sources, Clioquinol archive and Clioquinol research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Clioquinol”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Clioquinol” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.